Pharma | DCGI clears import of anti-anthrax vaccine1 min read . Updated: 23 Feb 2009, 10:11 PM IST
Pharma | DCGI clears import of anti-anthrax vaccine
New Delhi: The drug controller general of India (DCGI) has issued a registration certificate to import the anthrax vaccine BioThrax into India, an offcial at the DCGI office told Mint. The vaccine will be imported from US-based Emergent BioSolutions Inc. BioThrax is the only vaccine against anthrax that is licensed by the US food and drugs authority (FDA).
According to a statement released by Emergent BioSolutions, DCGI’s approval comes after the Indian National Disaster Management Authority published the National Disaster Management Guidelines in 2008 stating the need to have a supply of readily available anthrax vaccines in the event of an outbreak.
The marketing agent for BioThrax in India will be Hyderabad-based Biological E, which also won a major part of the government’s procurement for essential vaccines after the closure of the three public sector vaccine units last year.
Sun, Taro chiefs ‘in compromise talks’
Mumbai: The heads of Sun Pharmaceutical Ltd and Israeli firm Taro Pharmaceutical Industries Ltd are reported to have initiated talks to arrive at a compromise over the failed merger deal they signed in 2007.
Israeli business news website Globes said on Sunday, quoting unidentified persons, that Sun Pharma chairman and managing director Dilip Shanghvi and Taro chairman Barrie Levitt have started discussing a possible resolution to the takeover battle that is being fought in courts in the US and Israel. The legal proceedings started after Taro last year unilaterally terminated the merger deal. The report said that Mumbai-based Shanghvi and US-based Levitt flew to Israel to discuss a resolution that would enable Sun to acquire Taro. “The two met in the offices of lawyer Ram Caspi, who is mediating the compromise," along with senior representatives of US investment management firm Franklin Templeton, the website said.
Mint could not immediately confirm the development as a Sun spokesperson declined comment.
While Sun Pharma currently holds around 36% stake in Taro, Franklin Templeton owns 13.1%. After the merger deal collapsed in May 2008, Sun launched an open tender offer to buy Taro’s shares held by promoters and public shareholders in the US. But the tender offer was postponed after Israel’s Supreme Court asked the management of the companies to negotiate.